This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Janakiram, N. B. Articles by Rao, C. V. Search for Related Content PubMed PubMed Citation Articles by Janakiram, N. B. Articles by Rao, C. V. Related Collections Preclinical Intervention Preclinical Intervention: In Vivo (Animals): Drugs, Nutritional Interventions, Mechanisms Preclinical Intervention: Biomarkers

Estrogen Receptor-β as a Potential Target for Colon Cancer Prevention: Chemoprevention of Azoxymethane-Induced Colon Carcinogenesis by Raloxifene in F344 Rats

Authors' Affiliations: ¹ Department of Medicine, Hem-Onc Section, OU Cancer Institute, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma and ² Division of Cancer Prevention, Chemopreventive Agent Development Research, Rockville, Maryland

Requests for reprints: Chinthalapally V. Rao, Department of Medicine, Hem-Onc Section, OU Cancer Institute, University of Oklahoma Health Sciences Center, 975 Northeast 10th Street, BRC Building II, Room 1203, Oklahoma City, OK 73104. Phone: 405-271-3224; Fax: 405-271-3225; E-mail: cv-rao{at}ouhsc.edu.

Raloxifene, selective estrogen receptor (ER) modulator, is not fully explored in colorectal cancer. In the present study we, (a) investigated the effect of raloxifene on ER-positive colon cancer HCT-116 cell growth, (b) assessed the relevance of ER-β in colon tumorigenesis, and (c) assessed the chemopreventive efficacy of raloxifene against azoxymethane (AOM)-induced colon carcinogenesis using aberrant crypt foci (ACF) as surrogate end point marker. HCT-116 cells treated with raloxifene showed a significant decrease in cell growth associated with a decrease in ER-β expression levels. AOM-induced colon adenocarcinoma showed significant up-regulation of ER-β expression at both the protein and mRNA levels compared with normal mucosa, suggesting that ER-β is positively associated with colon cancer. An assay using five different dietary dose levels (0.31, 0.62, 1.25, 2.5, or 5 ppm) of raloxifene for 6 weeks in male F344 rats found the maximum tolerated dose to be 5 ppm. To evaluate inhibitory properties of raloxifene on colonic ACF, 7-week-old rats were fed experimental diets containing 0, 0.625, 1.25, and 2.5 ppm of raloxifene. After 1 week, rats received s.c. injections of AOM, 15 mg/kg body weight, once weekly for 2 weeks. Rats continued to receive respective experimental diets and sacrificed 8 weeks after the last AOM treatment. Raloxifene given in the diet significantly inhibited AOM-induced total colonic ACF (31-40%; P < 0.001-0.0005) and multicrypt (four or more) aberrant foci (23-50%; P < 0.05-0.005) in F344 rats. Our findings suggest that ER-β acts as a colon tumor promoter and raloxifene as an antagonist to ER-β, providing protection against colon carcinogenesis.

Key Words: colon cancer • chemoprevention • raloxifene • ER-β • aberrant crypt foci

This article has been cited by other articles:

				C. V. Rao, V. E. Steele, M. V. Swamy, J. M.R. Patlolla, S. Guruswamy, and L. Kopelovich Inhibition of Azoxymethane-Induced Colorectal Cancer by CP-31398, a TP53 Modulator, Alone or in Combination with Low Doses of Celecoxib in Male F344 Rats Cancer Res., October 15, 2009; 69(20): 8175 - 8182. [Abstract] [Full Text] [PDF]